Interchange of vaccine products; Revaccination with different COVID-19 vaccine; Suspected covid-19; This spontaneous case was reported by a patient and describes the occurrence of SUSPECTED COVID-19 (Suspected covid-19), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039021A) for COVID-19 prophylaxis.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 prophylaxis.    No Medical History information was reported.   On 10-Mar-2021, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. On 21-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2022, the patient experienced SUSPECTED COVID-19 (Suspected covid-19). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 22-Jun-2022 to 27-Jun-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, SUSPECTED COVID-19 (Suspected covid-19), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) outcome was unknown.            The age of the patient at the time of Janssen vaccination was 70 years. No concomitant medications were reported. For Janssen causality for event itchy extended hand size red puffy patches in several spots around upper legs and hip areas, suspected COVID-19 infection, rash increasing in size welts increasing in size especially at night was reported as possible and action taken reported as not applicable. After taking treatment drug Paxlovid on 24-Jun-2022 patient experienced rash increasing in strength each of the five day treatment, itchy welts increasing in size especially at night resulting in extended hand size red puffy patches in several spots simultaneously. The patient recovered from itchy, extended hand size red puffy patches in several spots around upper legs and hip areas, rash increasing in size and welts increasing in size especially at night in 2022.  Company Comment: This spontaneous case of Interchange of vaccine products concerns a 72-year-old male patient, with previous vaccination of JANSSEN COVID-19 VACCINE, who experienced the unexpected non-serious AESI of Suspected COVID-19. The event occurred on an unknown date interval after receiving a dose of mRNA-1273 Vaccine. The outcome of the events was reported as unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case of Interchange of vaccine products concerns a 72-year-old male patient, with previous vaccination of JANSSEN COVID-19 VACCINE, who experienced the unexpected non-serious AESI of Suspected COVID-19. The event occurred on an unknown date interval after receiving a dose of mRNA-1273 Vaccine. The outcome of the events was reported as unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.